AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.
| Website | http://www.adaptvac.com |
| Employees | 9 (7 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Vaccine Research, Vaccine Development, Vaccine Technology, Next Generation Vaccines, Viral Vector Vaccines, Biotechnology, Rna Vaccines, Immunotherapy, Immunology, Biopharma, Cancer Vaccines, Dna Vaccines, Pharmaceutical Research, Therapeutics, Drug Development, Clinical Trials, Vaccine Manufacturing, Drug Discovery |
| Competitors | Johnson & Johnson, Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Smith+Nephew, B. Braun Group, Olympus Corporation, CR Bard - Europe, Middle East and Africa (EMEA) +33 more (view full list) |
Looking for a particular AdaptVac employee's phone or email?
AdaptVac Questions
Wian de Jongh is the CEO of AdaptVac.
7 people are employed at AdaptVac.
Top AdaptVac Employees
-
Wian de Jongh
CEO at AdaptVac
Copenhagen, DK21 -
Allan Rosetzsky
Director of the Board at AdaptVac
Hørsholm, DK21 -
Louise Goksøyr
Scientist, Project Lead at AdaptVac
Copenhagen, DK1 -
Cyrielle Fougeroux
Team Leader at AdaptVac
Copenhagen, DK31 -
Sanna Vestergaard
Laboratory Manager at AdaptVac
Copenhagen, DK11 -
Sven Hagen
Scientist at AdaptVac
Copenhagen, DK2
Related Companies
